Navigation Links
MiMedx To Exceed High End Of Second Quarter Guidance
Date:7/15/2013

MARIETTA, Ga., July 15, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company will slightly exceed the $13.5 million high end of its previously communicated revenue range for second quarter of 2013.

The Company's second quarter of 2013 revenue represents an increase of greater than 175% over second quarter of 2012 revenue, and for the six months ended June 30, 2013, MiMedx revenue increased by more than 190% over its revenue for the first six months of 2012.  The Company reported that the second quarter of 2013 marks the 7th consecutive quarter in which MiMedx has met or exceeded its revenue guidance.

The Company also increased its guidance for the lower end of its full year 2013 revenue range. MiMedx reported that it now expects the Company's 2013 full year revenue to be in the range of $54 million to $60 million. Where revenue falls within this range is dependent on the reimbursement approval of the three remaining Medicare Contractors.

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
2. MiMedx Group Completes $5,000,000 Private Placement
3. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
4. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
5. MiMedx Group Announces 2011 Results
6. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
7. MiMedx Exceeds Revenue Goal for First Quarter of 2012
8. MiMedx Group Announces Record First Quarter Results
9. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
10. MiMedx Group Announces Record Second Quarter Results
11. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... participants committed to not only creating unique business card ... tweaking and testing virtual models and 3D test prints ... “I enjoyed being involved as a judge,” stated a ... a commendable range exploring the technical capabilities of the ... the creativity of the contestants.” , Array Architects is ...
(Date:10/1/2014)... CA (PRWEB) September 30, 2014 ... user-friendly, cost-effective tools to address sales, training and ... has developed innovative mobile applications to turn ... outlining the agency’s latest customized mobile app creations, ... http://www.studiopmg.com/work . , In partnership with Toyota, StudioPMG ...
(Date:10/1/2014)... 30, 2014 Award winning unified ... announces four new-hosted collaboration bundles that combine next ... quality conferencing experiences for low, flat rate fees. ... from, businesses have optimized solutions to meet their ... include audio only minutes (1K, 5K, 10K increments) ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 TeselaGen ... National Science Foundation to expand their bioCAD/CAM software suite, ... and modify DNA. The Small Business Innovation Research Phase ... “j5” technology under exclusive license from the Lawrence Berkeley ... BioEnergy Institute , an LBNL laboratory that develops alternative ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... - YM BioSciences Inc. (NYSE Amex: YMI ... company that identifies and advances a diverse portfolio ... development, today reported that its licensee for nimotuzumab, ... has commenced enrollment of a Phase II trial ...
... and to Complete Current Phase 3 Trial of Naturlose(R) ... June 23 Spherix Incorporated (Nasdaq: SPEX ... a provider of technical and regulatory consulting services to ... it has received its first full-scale production batch of ...
... Medical Device & Diagnostic Industry Magazine,s 30 Years, 30 Devices Special ... 23 Medical Device and Diagnostic Industry has recognized ... a leader in infusion therapy and pain management as well as ... as being among the most influential medical devices of the last ...
Cached Biology Technology:YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 2YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 3YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 4YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 5Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 2B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 3B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 4
(Date:9/29/2014)... Washington, DC Monday, September 29: Between 1970 ... and fish around the globe dropped 52 percent, ... by World Wildlife Fund (WWF). This biodiversity loss ... increasing resource use of high-income countries. , In ... the report,s data point to other warning signs ...
(Date:9/29/2014)... school? According to a new Food and Brand Lab ... can increase participation in the National School Lunch Program ... vegetables by 16%! , Chefs Move to Schools (CMTS), ... chefs with schools in order to provide nutrition instruction ... service workers. , A CMTS event was held in ...
(Date:9/29/2014)... team says recently identified radiation detection properties of a ... for homeland security and medical advances. , In a ... of Optics Letters , UT Arlington Physics Professor ... to fabricate transparent nanoscintillators by heating nanoparticles composed of ... formed. A scintillator refers to a material that ...
Breaking Biology News(10 mins):Half of global wildlife lost, says new WWF report 2Chefs move to schools can increase school meal participation and vegetable intake among students 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... y MUNICH, 7 de noviembre de 2012 Bausch + ... ejercitación de su opción de compra de todas las acciones ... Vision GmbH (TPV), una destacada compañía láser de oftalmología. ... de una sociedad mixta entre Bausch + Lomb y 20/10 ...
... 2012 Bausch + Lomb, a empresa global de saúde ... as ações em circulação e sem controle da Technolas ... A Technolas Perfect Vision foi criada em 2009 ... + Lomb e a 20/10 PERFECT VISION AG para desenvolver ...
... well known for attacking a protein associated with the ... it also degraded a different protein that triggers blood ... a key challenge in the battle against cancer, according ... in the University of Leeds, Faculty of Biological Sciences., ...
Cached Biology News:Bausch + Lomb adquiere Technolas Perfect Vision GmbH 2Bausch + Lomb adquiere Technolas Perfect Vision GmbH 3Bausch + Lomb adquiere Technolas Perfect Vision GmbH 4Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 2Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 3Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 4Breast cancer drug could halt other tumors 2
Rabbit polyclonal to hnRNP-U...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 250 units polymerase, ...
... (E.C. 3.1.21.1) is a nonspecific endonuclease that ... functions by hydrolyzing phosphodiester linkages, producing mono ... 3'-hydroxyl group. Ambion's RNase-free DNase I is ... recommended to degrade DNA in the presence ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
Biology Products: